Boehringer Ingelheim opens production site in Vienna
The Large-Scale Cell Culture Facility (LSCC) is one of the most advanced of its kind, according to the company, with a high degree of digitalization and automation through smart technologies and artificial intelligence applications.
Boehringer Ingelheim invested 700 million euros ($ 810 million) in the facility, which created 500 new jobs.
Capacities for different molecule formats
The facility adds 185,000 liters of biopharmaceutical production capacity to Boehringer Ingelheim’s global network, which represents an additional 30% of large-scale capacity for mammals.
A multi-product setup allows for the production of a wide variety of molecule formats, with the plant being designed to allow for changes from one product to another in a short period of time (or the production of different products at the same time).
The site can provide a variety of molecule formats, including monoclonal antibodies, enzymes, cytokines, and other recombinant proteins. It will cover the product portfolio of Boehringer Ingelheim as well as contract manufacturing by third parties.
Highly complex biopharmaceutical molecules play an important role in treating chronic and other serious illnesses, the company notes.
“The potential of biopharmaceuticals for future innovative treatments is growing rapidly. We are committed to investing in the development of additional production platforms for organic products based on the latest technologies ”,Said Hubertus von Baumbach, Chairman of the Board of Directors.
“There are still many patients today whose illnesses cannot yet be adequately treated. That’s why we strive to advance the science that will enable us to achieve the next medical breakthrough. “
Boehringer Ingelheim’s biopharmaceutical network operates four manufacturing sites worldwide in Asia, Europe and the United States: with its other sites in Biberach, Germany; Fremont, United States; and Shanghai, China.